文献速递母胎医学产科

外显子组测序后基因组测序在非免疫性胎儿水肿谱中的增量诊断价值

Incremental yield of genome sequencing after exome sequencing for nonimmune hydrops fetalis spectrum.
PubMed 文献 · Am J Obstet Gynecol MFM · 2026-07-18

该队列研究纳入118例非免疫性胎儿水肿谱(NIHFS)胎儿样本,均在核型/染色体微阵列分析(CMA)及外显子组测序(ES)结果非诊断性后行基因组测序(GS)。GS检出4个既往未发现的致病/可能致病变异,使3例获得新诊断,新增阳性检出率为2.5%(3/118)。

要点

  • 对ES后未确诊的NIHFS,GS可额外检出致病性拷贝数变异。
  • GS新增阳性诊断率为2.5%(3/118),幅度小但具临床意义。
  • GS还检出1个次要发现和4个意义不明变异(VUS)。

核心结论

  • GS在染色体检查和ES基础上对NIHFS有幅度小但具临床意义的增量诊断价值,尤其利于检出拷贝数变异。
  • 随着非编码区和复杂基因组变异解读能力提升,GS的增量阳性检出率预计将进一步增加。

研究设计与样本

  • 队列研究,纳入118例NIHFS胎儿样本,均在核型/CMA及ES结果阴性(n=102)或不确定(n=16)后行GS。
  • ES和GS在CLIA认证实验室完成,变异按美国医学遗传学与基因组学学会(ACMG)指南分类。
  • 主要结局为GS检出新的致病/可能致病(P/LP)变异并导致新诊断的比例。

主要发现

  • GS检出4个既往核型、CMA和ES均未检出的P/LP拷贝数变异,使3例妊娠获得新遗传诊断。
  • GS新增阳性检出率为2.5%(3/118)。
  • GS在4例不同妊娠中检出1个次要发现和4个VUS,这些额外发现主要源于分析工具和文献更新而非GS技术本身。

关键数值与推荐

  • NIHFS定义为存在至少一种病理性胎儿液体积聚:腹水、胸腔或心包积液、皮肤水肿、囊性水瘤和/或颈项透明层≥3.5 mm。
  • 纳入标准为核型/CMA和ES结果非诊断性。
  • GS新增阳性检出率为2.5%(3/118)。

临床怎么用

  • 对核型/CMA和ES均未确诊的NIHFS妊娠,可考虑追加GS以检出ES未覆盖的拷贝数变异。
  • GS检出的额外VUS和次要发现需谨慎解读,部分源于分析工具更新而非技术优势。

局限性

  • 样本量有限(118例),新增阳性例数少(3例)。
  • 额外发现多与更新分析工具和文献有关,而非GS技术特异性优势。
  • 非编码区和复杂基因组变异解读能力尚有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Exome sequencing (ES) detects a monogenic disorder in approximately 30% of pregnancies with unexplained nonimmune hydrops fetalis spectrum (NIHFS), defined as the presence of one or more pathologic fetal fluid collection. Since genome sequencing (GS) can identify additional genetic variants not detectable by ES, we sought to determine the proportion of cases with new reportable findings on GS following nondiagnostic standard of care testing, including ES, for NIHFS. STUDY DESIGN: Cohort study of pregnancies with NIHFS that had nondiagnostic results of karyotype and/or chromosomal microarray analysis (CMA) and ES. Eligible fetal fluid collections included at least one of: ascites, pleural or pericardial effusions, skin edema, cystic hygroma, and/or nuchal translucency ≥3.5 mm. Pregnancies with NIHFS that did not receive a clear diagnosis with prior testing underwent additional testing with GS. ES and GS were performed in a Clinical Laboratory Improvement Amendments-approved laboratory, and genetic variants were classified according to the American College of Medical Genetics and Genomics guidelines. Primary outcome was the proportion of new reportable pathogenic or likely pathogenic (P/LP) variants identified on GS and resulting in a new diagnosis. Secondary outcome was the incremental yield of GS for detecting new secondary findings and variants of uncertain significance (VUSs). RESULTS: Overall, 118 fetal samples underwent GS following negative (n=102) or inconclusive (n=16) ES. GS identified four P/LP copy number variants previously not detected by karyotype, CMA, or ES that led to a new genetic diagnosis in three pregnancies, providing a new positive finding yield of 2.5% (3/118). Additionally, one secondary finding and four VUSs were identified by GS in four different pregnancies. In contrast to the primary outcome, these additional findings were largely the result of updated analytical tools and literature rather than GS-specific technology. CONCLUSION: GS has a small but clinically relevant increased diagnostic yield over chromosome studies and ES for NIHFS, particularly for identifying copy number variants. As interpretation of noncoding regions and complex genomic variations improves, the incremental positive finding yield of GS is expected to further increase.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Boutin RCT, Lianoglou BR, Sahin Hodoglugil NN, et al. Incremental yield of genome sequencing after exome sequencing for nonimmune hydrops fetalis spectrum. Am J Obstet Gynecol MFM. 2026. PMID: 42471198. doi:10.1016/j.ajogmf.2026.102067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。